Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance
8/9/2022 12:00:00 AM2 years 8 months ago
by Verona Pharma plc
by Verona Pharma plc
Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD Top-line Phase 3 ENHANCE-1 data expected...
Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call toda… [+17488 chars]
full article...